Abstract 46P
Background
Breast cancer is one of the malignant diseases with the highest prevalence around the world, including Indonesia. Data from Global Cancer Statistics 2018 (GLOBOCAN) predicted that up to 2.1 billion women were diagnosed with breast cancer; therefore, it became one of the top four cancerous diseases in women. Several studies have revealed the role of CD36 molecule in breast cancer and there are several gaps in CD36 expression knowledge. In tumor adhesion, CD36 is involved in cellular interaction with collagen in the extracellular matrix. Some measurement methods of CD36 expression molecules include gene expression measurement through micro-assay, total RNA analysis, and plasma examination through ELISA techniques already done in subjects with non alcoholic fatty liver disease, diabetes mellitus, insulin resistance, coronary arterial disease, carotid atherosclerosis, chronic kidney disease, and ischaemic stroke. However, concentration measurement of CD36 plasma molecule in breast cancer using ELISA technique has not yet been done in previous studies.
Methods
This is a cross-sectional study, was held during June 2018 up to February 2019. Sampling methods were taken consecutively in 118 subjects, consisted of 76 BC subjects, 42 normal subjects. Inclusion criteria included women aged 18 to 70 years old, having pathological invasive breast cancers, and subjects were willing to sign the informed consent sheets. Exclusion criteria included subjects with disease progressivity during therapy, diabetes mellitus, stroke, liver, coronary arterial disease, chronic kidney disease. Subjects were then drawn 2 cc of the peripheral blood,and then was centrifuged in 3000 RPM for 15 minutes. After that, the plasma was analyzed with ELISA technique with reagent (Bioassay Technology Laboratory). Data was analyzed using SPSS for windows version 20.
Results
Table: 46P
Profile of plasma CD36 concentration
| Characteristic | Median concentration CD36 (ng/mL) | p |
|---|---|---|
| BC Healthy | 0.21 (-0.05 up to 0.70) 0.57 (0.13 up to 1.05) | 0.00 |
| Metastatic BC Non metastatic BC | 0.21 (-0.05 up to 0.70) 0.21 (-0.05 up to 0.70) | > 0.05 |
| BC with LN metastatic BC without LN metastatic | 0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70) | > 0.05 |
| Luminal tumor HER2 tumor Triple negative tumor | 0.21 (-0.05 up to 0.67) 0.21 (-0.02 up to 0.70) 0.22 (-0.02 up to 0.36) | > 0.05 |
| G1 G2 G3 Unknown grade | 0.23 (0.16 up to 0.70) 0.21 (-0.05 up to 0.70) 0,20 (-0,02 up to 0,67) 0.22 (0.10 up to 0.53) | > 0.05 |
| Tumor size > 2 cm Tumor size ≤ 2 cm | 0.21 (-0.05 up to 0.70) 0.26 (0.13 up to 0.70) | > 0.05 |
| BC with BMI≥ 23 BC with BMI < 23 | 0.20 (-0.05 up to 0.70) 0.23 (-0.05 up to 0.70) | > 0.05 |
Conclusions
Plasma CD36 concentration of breast cancer is lower than the healthy. There are insignificant differences of plasma CD36 concentration profile breast cancer patients based on metastatic status, lymph node metastatic, molecular subtype, invasive cancer histologic grade, and body mass index.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Ethics Committee of The Faculty of Medicine, University of Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract